Even though death is a certainty, we are all going to spend lots of money to guard against it.
Sarasin has so far been known primarily for its EquiSar fund range, the pioneer of thematic funds before they became fashionable. It is now launching the global health fund under the stewardship of Dr Irene Puttner and her experienced team.
Sarasin itself has a long association with the pharmaceutical industry.
Nothing touches our lives quite so poignantly as health. The impact of the genomic revolution, technological advances and ground-breaking research will lead to exciting opportunities in the fields of prevention and cure against a background of a rapidly ageing population.
In 20 years time,20-25 per cent of the population of industrialised nations will be over 65. That has got to benefit our industry.
Sarasin's fund will opt for around 40 per cent in pharmaceutical companies, 30 per cent in the medical technology field and the rest in biotechnology. It will have some 65 holdings, inevitably with a major emphasis on America, incorporating Sarasin's thematic top-down appraisal of key trends.
It has produced a first-class brochure outlining the enormous potential in this sector. It is important to compare the fund with others, such as Schroder medical discovery, Franklin, Framlington, Britannic and First State, to name a few.
As part of a global growth portfolio, healthcare-type funds can offer significant potential, admittedly often at higher risk and Sarasin deserves to be considered alongside the established players.
Michael Owen is joint managing director of Plan Invest Group